All In Biotech

Drug Trial Radar · NCT05840211

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy

Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 654 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

654

Planned (sponsor's estimate)

Start

May 8, 2023

Primary completion

Apr 2028

Study completion Apr 2028

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
May 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available standard treatments, such as paclitaxel, nab-paclitaxel or capecitabine. The primary objective is to compare the effect of SG relative to the treatment of physician's choice (TPC) on progression-free survival (PFS).

Conditions

  • Locally Advanced or Unresectable Metastatic Breast Cancer
  • Stage IV Breast Cancer

Interventions

  • Sacituzumab Govitecan-hziyDrug

    Administered intravenously

  • PaclitaxelDrug

    Administered intravenously

  • Nab-paclitaxelDrug

    Administered intravenously

  • CapecitabineDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Time frame: Up to approximately 29 months

Locations

288 sites in 28 countries. Site status is shown where the registry gives one.

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Chandler, Arizona

  • Los Angeles Hematology Oncology Medical Group

    Los Angeles, California

  • Stanford Cancer Institute

    Palo Alto, California

  • University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Rocky Mountain Cancer Centers, LLP

    Littleton, Colorado

  • Yale-New Haven Hospital-Yale Cancer Center

    New Haven, Connecticut

  • Investigational Drug Services, AdventHealth Orlando

    Altamonte Springs, Florida

  • Florida Cancer Specialists

    Brooksville, Florida

  • Florida Cancer Specialist

    Leesburg, Florida

  • Florida Cancer Specialist

    St. Petersburg, Florida

  • Piedmont Cancer Institute

    Atlanta, Georgia

  • Georgia Cancer Specialist - Annex

    Atlanta, Georgia

  • Northwest Georgia Oncology Centers

    Marietta, Georgia

  • The University of Kansas Hospital

    Kansas City, Kansas

  • Hematology Oncology Clinic

    Baton Rouge, Louisiana

  • Saint Luke's Cancer Institute

    Kansas City, Missouri

  • David C. Pratt Cancer Center

    St Louis, Missouri

  • Astera Cancer Care

    East Brunswick, New Jersey

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Stefanie Spielman Comprehensive Breast Center

    Columbus, Ohio

  • Penn State Cancer Institute

    Hershey, Pennsylvania

  • Magee-Womens of UPMC

    Pittsburgh, Pennsylvania

  • Prisma Health - Upstate

    Greenville, South Carolina

  • Tennessee Oncology, PLLC

    Nashville, Tennessee

  • Vanderbilt University Medical Center - Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • US Oncology Investigational Products Center (IPC)

    Fairfax, Virginia

  • US Oncology Investigational Products Center (IPC)

    Norfolk, Virginia

  • MultiCare Regional Cancer Center - Auburn

    Auburn, Washington

  • Hospital Britanico de Buenos Aires

    Buenos Aires, Argentina

  • Instituto de Investigaciones Clinicas de Mar del Plata

    Buenos Aires, Argentina

  • Instituto Alexander Fleming

    C.a.b.a., Argentina

  • Hospital Alemán

    CABA, Argentina

  • Centro Privado de RMI Rio Cuarto S.A.

    Córdoba, Argentina

  • Instituto de Oncología de Rosario

    Rosario, Argentina

  • CER San Juan Centro Polivalente de Asistencia e Investigación Clínica

    San Juan, Argentina

  • Royal Brisbane and Women's Hospital

    Queensland, ME, Australia

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

Showing 40 of 288 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.